Business Wire

ADANI-ENTERPRISES

2.6.2024 18:10:35 CEST | Business Wire | Press release

Share
Stronger Than Ever: Adani Portfolio Delivers Record Performance

In line with their commitment to upholding the highest standards of transparency, below is the Adani Portfolio’s Credit and Result compendium for financial year 2023-24.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240602830505/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Consistently improving financial performance (in INR crore) - in charts (Graphic: Business Wire)

The performance in FY24 and the past five years signify the strength and stability of the Adani Portfolio and the robustness of its businesses, which despite all external volatilities and headwinds, continue to deliver strong and consistent growth. It also highlights the superior capital allocation strategy that maximises returns and minimises risks.

Adani Portfolio reports strongest financial results till date

In FY24, the Adani Portfolio of companies rose to its best, showcasing resilience, strength and stability and delivering a record EBITDA growth of 45%. With surging cashflows and enhanced credit profiles, the Adani Portfolio is in a ‘stronger than ever’ position to accelerate growth.

  • EBITDA: Consistently advancing EBITDA increased to USD 10 Bn with record 45% growth year-on-year, highest in the history of the Adani Portfolio.
  • Cash Profit or FFO: Cash Profit of Funds Flow from Operations (FFO) was at USD 6.7 Bn, registering a growth of 51% year-on-year, thanks to its disciplined investment strategy providing high conversion of EBITDA into cash profit.
  • Core infrastructure EBITDA: The core infra and utility platform generated USD 8.3 Bn or 84% of the total EBITDA. The user base of the platform increased to over 350 million, with a fast-growing consumer franchise across airports, electricity distribution, smart metering, gas distribution and direct to consumer digital platform.
  • Gross Assets: Total Gross Assets increased by USD 8 Bn or 16% and now stand at USD 57.4 billion.
  • Conservative leveraging: Rising cash profit lowered the net leverage significantly. Net Debt to EBITDA is down from 3.3x at the end of FY23 to 2.2x, notably lower than the industry benchmark.
  • Liquidity position: Cash reserves of USD 7.2 Bn at the portfolio level was the highest ever, up 48.5% from last year and was at 24.8% of gross debt.
  • Ratings: Predictable cashflows led to multiple rating upgrades across portfolio companies. Adani Ports and Special Economic Zone became the first largescale Indian infrastructure company to be rated ‘AAA’. Now, three listed portfolio companies — APSEZ, Ambuja Cement and ACC — have the highest INR rating of ‘AAA’. There are two ‘AAA’ rated entities under AESL, namely Alipurduar Transmission and Western Transmission.
  • Diversified funding sources: The Adani Portfolio debt profile represents a balanced exposure to domestic banking, global banking and capital markets. Of the total debt mix, domestic banking exposure stands at 36% and domestic capital markets at 5% whereas 26% is the exposure to the global banking market; the global capital market is at 29% and the balance 4% is with others.

For compendiums download:

https://www.adani.com/-/media/Project/Adani/Invetsors/Q4%20FY24%20Performance

About The Adani Portfolio of Companies

Headquartered in Ahmedabad, the Adani portfolio is the largest and fastest-growing portfolio of diversified businesses in India with interests in logistics (seaports, airports, shipping and rail), resources, power generation and distribution, renewable energy, gas and infrastructure, agro (commodities, edible oil, food products, cold storage and grain silos), public transport infrastructure, defence, and other sectors. Adani owes its success and leadership position to its core philosophy of ‘Nation Building’ and ‘Growth with Goodness’, a guiding principle for sustainable growth. The Portfolio is committed to protecting the environment and improving communities through its CSR programmes based on the principles of sustainability, diversity, and shared values.

Further information at www.adani.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240602830505/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye